Login to Your Account


PERTH, Australia – Australia's Imugene Ltd. could be the first biotech out of the gate in developing B-cell peptide vaccines in the immune-oncology space.

Circle Pharma Inc., of South San Francisco, said its first collaboration with Pfizer Inc. has led to the identification of a series of bioavailable macrocyclic peptides capable of acting as potent and cell-permeable modulators of CXCR7.

DUBLIN – The twin phenomena of protein aggregation and deposition have been viewed almost exclusively through a pathology lens. The amyloid hypothesis in Alzheimer's disease – still not conclusively proven in clinical settings but by no means refuted either – is the most prominent example in human biology.

More Newco News Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: